Vaccines Market Will Reach $33.8bn in 2012

Thursday 6 September 2012, Amsterdam

A new report predicts that the 2012 world market for vaccines to treat human beings will reach $33.8 bn. That revenue forecast appears in World Vaccines Market 2012-2022, published in July 2012.

Paediatric vaccination is the traditional cornerstone of the market, and this segment continues to dominate, with the forthcoming release of Bexsero (Novartis’ vaccine against meningitis B) set to enlarge the market. However, increased vaccination of adults and growing penetration of therapeutic vaccines in the cancer treatment market will drive the next phase of growth through to 2022, the study notes.

Dr James Evans, a pharmaceutical industry analystsaid: “Pfizer’s Prevnar-13, the biggest vaccine franchise in the world in 2011 with sales of $3.7bn, is soon to be extended to adults. It’s the first multi-billion dollar vaccine franchise, and it will replace Lipitor as Pfizer’s biggest product.

“That’s a symbolic moment: vaccines are joining other biological products as the main driver for the pharmaceutical industry overall. The expansion of the therapeutic vaccines segment will accelerate that process, with vaccine treatments for melanoma, ovarian and lung cancers in the next ten years.”